

Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/MB9B5AFBF3FFEN.html>

Date: March 2020

Pages: 82

Price: US\$ 3,500.00 (Single User License)

ID: MB9B5AFBF3FFEN

Abstracts

Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H1 2020

SUMMARY

Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 17 molecules. The latest report Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H1 2020, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 8 and 3 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Neurology, Pain, Parkinson's Disease, Presbyopia, Rett Syndrome, Sialorrhoea and Tuberos Sclerosis.

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)

The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects

The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

AstraZeneca Plc

Cerevel Therapeutics LLC

Karuna Therapeutics Inc

NeuroHealing Pharmaceuticals Inc

NeuroSolis Inc

Presbyopia Therapies LLC

Sosei Heptares

Suven Life Sciences Ltd

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles

(aceclidine + tropicamide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones

Featured News & Press Releases

Feb 24, 2020: Anavex Life Sciences announces publication of foundational data for ANAVEX2-73 (blarcamesine) in multiple sclerosis (MS)

Feb 03, 2020: Anavex Life Sciences announces Fast Track Designation granted by U.S. FDA for ANAVEX2-73 (blarcamesine) clinical development program for the treatment of Rett Syndrome

Jan 27, 2020: Anavex Life Sciences announces achievement of enrollment target for the ANAVEX2-73 (blarcamesine) phase 2 Parkinson's Disease Dementia (PDD) clinical trial

Jan 08, 2020: Anavex Life Sciences issued new U.S. patent for ANAVEX2-73 treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis

Dec 04, 2019: Anavex Life Sciences presents ANAVEX2-73 (blarcamesine) data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 conference

Nov 19, 2019: Karuna Therapeutics' schizophrenia drug passes Phase II trial

Nov 18, 2019: Karuna Therapeutics announces KarXT met primary endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

Nov 17, 2019: Karuna Therapeutics schedules webcast and conference call to announce results from its phase 2 clinical trial of KarXT for the treatment of Psychosis in patients with Schizophrenia

Nov 14, 2019: Anavex Life Sciences receives Rare Pediatric Disease Designation from FDA for ANAVEX2-73 (blarcamesine) for the treatment of Rett Syndrome

Nov 06, 2019: Anavex Life Sciences announces publication of foundational data for ANAVEX2-73 (blarcamesine) in Rett Syndrome

Oct 21, 2019: Cerevel Therapeutics initiates phase 1b clinical trial of CVL-231, a M4 selective positive allosteric modulator in development for the treatment of schizophrenia

Oct 10, 2019: Anavex initiates ANAVEX 2-73 study in Alzheimer disease

Oct 02, 2019: Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX2-73 for the Treatment of Alzheimer's Disease

Sep 27, 2019: Anavex Life Sciences presented at the 6th Annual European Rett Syndrome Conference preliminary clinical efficacy data from the U.S. Rett Syndrome Phase 2 ANAVEX2-73 Study

Sep 16, 2019: Anavex Life Sciences announces preliminary clinical efficacy data of its U.S. phase 2 clinical trial of ANAVEX 2-73 in patients with Rett Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Anavex Life Sciences Corp, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Cerevel Therapeutics LLC, H1 2020
Pipeline by Karuna Therapeutics Inc, H1 2020
Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2020
Pipeline by NeuroSolis Inc, H1 2020
Pipeline by Presbyopia Therapies LLC, H1 2020
Pipeline by Sosei Heptares, H1 2020
Pipeline by Suven Life Sciences Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Anavex Life Sciences Corp

AstraZeneca Plc

Cerevel Therapeutics LLC

Karuna Therapeutics Inc

NeuroHealing Pharmaceuticals Inc

NeuroSolis Inc

Presbyopia Therapies LLC

Sosei Heptares

Suven Life Sciences Ltd

I would like to order

Product name: Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/MB9B5AFBF3FFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MB9B5AFBF3FFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970